Therapeuitics

Healthcare pricing reform has been a goal for patients and politicians for decades, but a provision in a 2003 Medicare overhaul prohibited the US federal government from negotiating prices with pharma companies. In the latest Smart Thinking Blog, Rohit Khanna of Catalytic Health describes how the Inflation Reduction Act’s drug pricing negotiation provision is, and isn’t, the holy grail of healthcare pricing reform.